Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) have been given an average rating of “Hold” by the eight ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $22.20.

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price objective on shares of Ocular Therapeutix in a research report on Monday, September 25th. ValuEngine lowered Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 21st. Zacks Investment Research lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Guggenheim assumed coverage on Ocular Therapeutix in a research report on Monday, October 23rd. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Ocular Therapeutix in a research report on Wednesday, November 8th.

In other news, Chairman Amarpreet Sawhney purchased 19,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were bought at an average cost of $5.18 per share, for a total transaction of $98,420.00. Following the completion of the transaction, the chairman now directly owns 696,390 shares of the company’s stock, valued at approximately $3,607,300.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel M. Bollag purchased 24,700 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were purchased at an average price of $3.93 per share, for a total transaction of $97,071.00. Following the completion of the transaction, the insider now directly owns 24,700 shares of the company’s stock, valued at $97,071. The disclosure for this purchase can be found here. Insiders have purchased 69,500 shares of company stock worth $304,781 over the last 90 days. 26.10% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. TIAA CREF Investment Management LLC boosted its position in shares of Ocular Therapeutix by 0.7% during the second quarter. TIAA CREF Investment Management LLC now owns 111,019 shares of the biopharmaceutical company’s stock valued at $1,029,000 after purchasing an additional 785 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Ocular Therapeutix by 10.8% during the second quarter. Nationwide Fund Advisors now owns 12,344 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 1,204 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Ocular Therapeutix by 4.4% during the second quarter. Goldman Sachs Group Inc. now owns 33,417 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 1,422 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of Ocular Therapeutix by 6.2% during the second quarter. Teachers Advisors LLC now owns 42,679 shares of the biopharmaceutical company’s stock valued at $396,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Ocular Therapeutix by 0.4% during the second quarter. Vanguard Group Inc. now owns 905,456 shares of the biopharmaceutical company’s stock valued at $8,394,000 after purchasing an additional 3,194 shares in the last quarter. Institutional investors own 52.94% of the company’s stock.

Ocular Therapeutix (NASDAQ OCUL) opened at $4.83 on Friday. The company has a current ratio of 4.79, a quick ratio of 4.78 and a debt-to-equity ratio of 0.39. Ocular Therapeutix has a 1 year low of $3.30 and a 1 year high of $11.79. The stock has a market capitalization of $140.35, a P/E ratio of -2.13 and a beta of 1.32.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.54). Ocular Therapeutix had a negative return on equity of 126.31% and a negative net margin of 3,241.19%. The business had revenue of $523.00 million for the quarter, compared to analyst estimates of $0.52 million. During the same period last year, the company earned ($0.39) EPS. Ocular Therapeutix’s revenue for the quarter was up 9.6% compared to the same quarter last year. analysts predict that Ocular Therapeutix will post -2.37 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/05/ocular-therapeutix-inc-ocul-given-consensus-rating-of-hold-by-analysts.html.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.